Quarterly report [Sections 13 or 15(d)]

Revenue - Collaboration Agreement - The Genentech Collaboration and License Agreement (Details)

v3.25.1
Revenue - Collaboration Agreement - The Genentech Collaboration and License Agreement (Details) - USD ($)
3 Months Ended 12 Months Ended
Apr. 12, 2024
Mar. 31, 2025
Jun. 30, 2024
Dec. 31, 2024
Sep. 23, 2024
Revenue          
Aggregate amount of the transaction price that is allocated to performance obligations   $ 121,973,000      
Revenue in the period       $ (3,217,000)  
Strategic Collaboration and License Agreement          
Revenue          
Aggregate remaining transaction price that had not yet been recognized as revenue $ 146,301,000        
Amount of cumulative catch-up adjustment at the date of the termination $ 101,348,000        
Revenue in the period     $ (20,741,000)    
Payments of milestone         $ 12,500,000
Amount of deferred income that was subsequently recognized as revenue due to the contract ending   25,298,000      
Payments of additional milestone   12,500,000      
Total revenue recognized on termination of the contract   $ 37,798,000